Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations

Investigational New Drugs

Volumn 16, Issue 4, 1998, Pages 303-313

  Shalinsky, David R ^a   Brekken, John ^a   Zou, Helen ^a   Kolis, Stan ^b   Wood, Alexander ^b   Webber, Stephanie ^a   Appelt, Krzysztof ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

AG3340; Athymic nude mice; Colon carcinoma; Gelatinase; Metalloprotease inhibitor; Metalloprotease(s)

Indexed keywords

METALLOPROTEINASE INHIBITOR; PRINOMASTAT;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; EXPERIMENTAL NEOPLASM; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MASS SPECTROMETRY; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; MICE, NUDE; ORGANIC CHEMICALS; PROTEASE INHIBITORS;

EID: 0032449008     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006204901140     Document Type: Article

References (19)

1. Levy DE, Ezrin AM: Matrix metalloprotease inhibitor drugs. In: Emerging Drugs: The Prospective for Improved Medicines. Ashley Publications Ltd., 1997
2. Wojtowicz-Praga SM, Dickson RB, Hawkins M: Matrix metalloprotease inhibitors. Invest New Drugs 15: 61-75, 1997
3. Morphy JR, Millican T, Porter JR: Matrix metalloprotease inhibitors: current status. Curr Med Chem 2: 743-762, 1995
4. Ray JM, Stetler-Stevenson WG: Matrix metalloproteinases and malignant disease: recent developments. Exp Opin Invest Drugs 5: 323-335, 1996
5. Hua J, Muschel RJ: Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 56: 5279-5284, 1996
6. Brown PD: Matrix metalloproteinase inhibitors in the treatment of cancer. Med Oncol 14: 1-10, 1997
7. Bender SL: Structure-based design of MMP inhibitors: discovery and development of AG3340. 214th National Meeting of the American Chemical Society, Las Vegas, NV, 1997
8. Santos O, McDermott CD, Daniels RG, Appelt K: Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteases. Clin Exp Metastasis 15: 499-508, 1997
9. Shalinsky DR, Brekken J, Varki NV, Robinson SR, Daniels R, Kolis S, Bansal S, Zou H, Bender S, Zook S, Margosiak S, Wood AW, Webber S, Appelt K: Marked inhibition of the proliferation of human adenocarcinoma colon tumors in vivo by orally-administered AG3340, a novel matrix metalloproteinase inhibitor. Proc Am Assoc Cancer Res 39: A2059, 1998
10. Neri A, Goggin B, Kolis S, Brekken J, Khelemskaya N, Gabriel L, Robinson SR, Webber S, Wood AW, Appelt K, Shalinsky DR: Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in lung after IV-tail implantation in C57BL/6 mice. Proc Am Assoc Cancer Res 39: A2060, 1998
11. Price A, Rewcastle NB, Yong VW, Zhong QS, Brasher P, Morris MG, Spencer D, Edwards D, Appelt KA, Forsyth P: Marked inhibition of tumor growth in a malignant glioma tumor model by the novel, synthetic matrix metalloproteinase (MMP) inhibitor, AG3340. Proc Am Assoc Cancer Res 39: 2061, 1998
12. Shalinsky DR, Brekken J, Zou H, Bender S, Zook S, Appelt K, Webber S, Varki NV: Increased apoptosis in human androgen-independent prostatic PC-3 tumors following oral administration of a novel matrix metalloproteinase (MMP) inhibitor, AG3340, in male nude mice. Proc Am Assoc Cancer Res 39: A4400, 1998
13. Johnston MR, Mullen JBM, Pagura M, Appelt KA, Shalinsky DR: AG3340, a novel matrix metalloproteinase (MMP) inhibitor, inhibits the growth of human large cell lung cancer tumors orthotopically implanted into the lung of athymic nude rats. Proc Am Assoc Cancer Res 39: A2060, 1998
14. Collier MA, Yuen GJ, Bansal SK, Kolis S, Chew TG, Appelt K, Clendinin NJ: A Phase I study of the matrix metalloproteinase (MMP) inhibitor, AG3340 given in single doses to healthy volunteers. Proc Am Assoc Cancer Res 38: A1491, 1997
15. Quinn LA, Moore GE, Morgan RT, Woods LK: Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions. Cancer Res 39: 4914-4924, 1979
16. Hibner B, Cad A, Flynn C, Casazza AM, Taraboletti G, Rieppi M, Giavazzi R: BAY 12-9566, a novel, biphenyl matrix metalloproteinase inhibitor, demonstrates anti-invasive and anti-angiogenic properties. Proc Am Assoc Cancer Res 39: 2063, 1998
17. Krane SM: Is collagenase (matrix metalloproteinase-1) necessary for bone and other connective tissue remodeling? Clin Orthop 313: 47-53, 1995
18. Yocum S, Lopresit-Morrow L, Reeves L, Mitchell P: MMP-13 and MMP-1 expression in tissues of normal articular joints. Proc NYAS, Second Conference on Inhibition of Matrix Metalloproteinases: Therapeutic Applications. Tampa, FL, 10/21-24/98
19. Itoh T, Tanioka M, Yoshida H, Yoshida T, Nishimoto H, Itohara S: Reduced angiogenesis and tumor progression in gelatinase-A deficient mice. Cancer Res 58: 1048-1051, 1998